A peer-reviewed, evidence-based journal that promotes clinical development and metabolic insights in total bariatric patient care for the healthcare professional
Issue link: http://bariatrictimes.epubxp.com/i/295392
S U R G I C A L P A I N
M A N A G E M E N T
H O T T O P I C S I N
C L I N I C A L , E V I D E N C E - B A S E D
I N F O R M A T I O N
V O L U M E 1 1 , N U M B E R 5 •
M A Y 2 0 1 4 • S U P P L E M E N T A
THE ROLE OF MULTIMODAL ANALGESIA IN
A Review of Clinical Data and Case-Based Presentations
Chief of Surgery, Baptist Hospital of Miami;
Medical Director, Bariatric Surgery,
South Miami Hospital;
Assistant Professor of Surgery,
Florida International University
College of Medicine, Miami, Florida
Anthony Gonzalez, MD
Anesthesiologist, Flagler Hospital,
St. Augustine, Florida
(acetaminophen) Injection is indicated for the management of mild to moderate pain; the management of moderate to
severe pain with adjunctive opioid analgesics; and the reduction of fever.
WARNING: RISK OF MEDICATION ERRORS AND HEPATOTOXICITY
Take care when prescribing, preparing, and administering OFIRMEV injection to avoid dosing errors which could result in
accidental overdose and death.
OFIRMEV contains acetaminophen. Acetaminophen has been associated with cases of acute liver failure, at times resulting in
liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed
the recommended maximum daily limits, and often involve more than one acetaminophen-containing product.
Patrick Ziemann-Gimmel, MD
To report SUSPECTED ADVERSE REACTIONS, contact Cadence Pharmaceuticals, Inc. at 1-877-647-2239 or FDA at 1-800-FDA-
1088 or www.fda.gov/medwatch.
Please see accompanying full Prescribing Information, including complete Boxed Warning.
©2014 Cadence Pharmaceuticals, Inc. All rights reserved. OFV13790214
EDITED-Cadence Ofirmez Suppl copy 2_Layout 1 4/15/14 10:02 AM Page A1